These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Exempt, with results 2006-002692-41 Safety of AM-101 in Patients with Acute Inner Ear Tinnitus from Noise Trauma: a Dose-Finding Phase I/II Study 2008-03-15 not-yet-due
Reported results 2008-000132-40 Efficacy of AM 111 in Patients with Acute Sensorineural Hearing Loss: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalation Phase II Study 2015-03-17 due-trials
Reported results 2008-005178-10 Efficacy of AM 101 in Patients with Acute Inner Ear Tinnitus: A Multi-Centre, Double-Blind, randomised, Placebo-Controlled, Multiple Dose, Group Comparison Phase II Study 2011-05-10 due-trials
Not reported 2009-009037-14 A randomised, blinded, phase IIa, placebo controlled, parallel group study to assess the efficacy, safety and tolerability of repeat doses of thymol solution 4% administered to the outer ear canal of ... 2010-05-17 due-trials
Reported results 2011-005384-24 TACTT1 2013-05-21 due-trials
Not reported 2012-004099-20 Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 3 (TACTT3) 2017-12-28 due-trials
Not reported 2013-001527-39 AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) – an open-label extension to the TACTT3 study 2016-12-19 due-trials
Not reported 2013-002077-21 Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss 2017-09-29 due-trials
Reported results 2013-005587-26 Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2 (TACTT2) 2016-06-22 due-trials
Reported results 2013-005588-24 AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) – an open-label extension to the TACTT2 study 2017-01-19 due-trials
Not reported 2016-005166-58 Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT) 2017-11-28 due-trials